Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM005-Granulae for prevention of nocturnal hypoglycemia in type 1 diabetes
2004-002070-36Phase 2Terminated
- Sponsor
- Metcon Medicin
- Start
- Dec 2004
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of istiratumab in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Metcon Medicin. Primary endpoint: Proportion of nights with at least one biochemical hypoglycemic event. Started Dec 2004; status: terminated.
02
Drugs
istiratumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2004-002070-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002070-36.